You buy fish oil for the omega-3, and the number printed largest on the front of the pack is usually the one that will not tell you how much you are getting. "1,000 mg fish oil" or "4,000 mg fish oil" is the weight of the oil in the capsule. The eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) inside it, the two fatty acids the research actually measures, usually add up to less. The supplement facts panel on the back is where the useful comparison starts.
This guide covers three things worth knowing before you buy: how much EPA and DHA the research supports, how to read a label so you know what you are getting, and who the outcome evidence genuinely applies to.
How much omega-3 do you actually need?
The tidy answer most people want, a single daily milligram target, is one the research does not provide. EPA and DHA are long-chain omega-3 fatty acids that get built into cell membranes, where they feed enzymatic pathways producing specialised pro-resolving mediators 1. That role turns up across cognition, cardiovascular and metabolic research, which is why the same two molecules get studied at very different doses for very different reasons.
Cognition is where the gap between hope and evidence is widest. A 2025 dose-response meta-analysis pooled 58 randomised trials, in people ranging from healthy adults to those with mild cognitive impairment or dementia, at doses and durations that varied widely 2. Pooled results were often non-significant for attention, executive function, perceptual speed and episodic memory. The review pointed to 1,000 to 2,500 mg a day as the window most consistently linked to an effect, though the one significant overall-cognition result carried low certainty and signs of publication bias.
A 2026 trial makes the limit concrete. Researchers gave 365 adults aged 55 to 80 with low DHA intake and a dementia risk factor either 2 g of DHA daily or placebo for two years 3. The DHA reached the brain, measured as higher cerebrospinal-fluid DHA at six months, while cognition and brain structure did not differ between the two groups. The supplement did what it was meant to do biologically, without moving the outcomes the trial set out to measure.
One practical reframe some clinicians use is to check status rather than chase a dose. The Omega-3 Index reports EPA plus DHA in red-blood-cell membranes as a percentage of total fatty acids, proposed in 2004 with provisional risk zones at or below 4% and at or above 8% 7. It remains a research threshold rather than a settled target, and it reflects your longer-term intake more steadily than any single meal. If you are considering higher amounts, an index reading with your GP is a more grounded place to start than a number off a bottle.
Is your fish oil giving you what you think?
This is the one piece of label-reading that pays off. Turn the pack over and read four figures off the supplement facts panel on the back rather than the marketing on the front:
- EPA per measured serving.
- DHA per measured serving.
- How many servings the adult direction actually uses each day.
- The other active ingredients and allergens in the full formula.
Those four separate oil weight from active fatty-acid content, and they show where a fish oil overlaps with anything else you already take. A product labelled "4,000 mg fish oil" and one labelled "2,000 mg EPA and 800 mg DHA" can be the same bottle described two ways, and only the second description lets you line it up against a trial.
Form matters less than people are often told, but it is worth knowing. Fish oils come as triglycerides (fatty acids on a glycerol backbone) or ethyl esters (attached to ethanol, which allows a more concentrated product). Small single-dose studies found that both the chemical form and the meal it is taken with affect short-term absorption, and a high-fat meal raised absorption from both forms [8,9]. The usable takeaway is short: read the labelled EPA and DHA, and take the oil with a meal that contains some fat.
Who actually benefits?
The clearest outcome evidence sits in high cardiovascular risk rather than the general well population. A 2025 meta-analysis of 42 trials and 176,253 adults with established cardiovascular disease or raised risk found lower risk for some cardiovascular outcomes, with no significant effect on all-cause mortality or stroke 4. The same analysis reported higher rates of atrial fibrillation and gastrointestinal side effects, so the benefit and the harms travel together and belong to that clinical population.
Two large trials show why "omega-3" is too loose a description to inherit a result:
- REDUCE-IT gave 8,179 statin-treated patients with high triglycerides plus cardiovascular disease or diabetes 4 g daily of prescription pure-EPA icosapent ethyl. It lowered the trial's composite cardiovascular endpoint 5.
- STRENGTH gave 13,078 similar high-risk patients 4 g daily of a mixed EPA+DHA formulation. It found no difference in major cardiovascular events, and gastrointestinal side effects were more frequent on the omega-3 6.
Same headline nutrient, different molecule, different comparator, different result. A prescription pure-EPA medicine in a defined high-risk group is its own intervention, and an over-the-counter mixed fish oil cannot borrow its outcome.
So who is a retail fish oil actually for? People with low dietary omega-3 intake who want to raise their status, and people managing cardiovascular risk under a clinician who is weighing the atrial-fibrillation trade-off. For a healthy adult hoping to sharpen memory, the current trial evidence stops short of promising a measurable change, which is worth knowing before you commit to a daily habit.
What about side effects?
The reason to avoid assuming more is automatically better sits in the same trials that show the benefit. High-dose use in high-risk adults raised gastrointestinal complaints, and pooled analyses found more atrial fibrillation in some settings [4,6]. Anyone with cardiovascular disease, an atrial-fibrillation history, prescription medicines, or who is pregnant or breastfeeding should have higher-dose use reviewed by a clinician first.
Fish and soy allergens, storage, and the full daily amount are part of a safe comparison too. Formulations and directions change, so read the label on the bottle you actually receive.
Compare the two products
Both fish oils in our range use concentrated oil, but their EPA:DHA ratios, added ingredients and adult directions differ, so they suit different reasons for taking one.
| Product | Amount per measured serving | Adult label and duration | Complete-formula notes | Evidence limit |
|---|---|---|---|---|
| MetaPure EPA/DHA | Per 4.2 mL: 2,000 mg EPA and 800 mg DHA from 4,000 mg concentrated triglyceride fish oil | 4.2 mL daily with meals; about 47 servings per 200 mL bottle | Citrus-berry liquid; contains fish; refrigerate after opening | High EPA and DHA content matches the scale of some trials, though this finished product was not the prescription intervention used in REDUCE-IT. |
| Omega Brain Plus | Per 5 mL, the supplying-partner panel lists 1,150 mg DHA, 346 mg EPA, 150 mg soy phosphatidylserine, 520 mg phosphatidylcholine, 160 mg palm tocotrienols and 500 IU vitamin D3. The current Metagenics NZ page instead lists 1,200 mg DHA. | 5 mL twice daily; 38 measured doses or 19 days per 190 mL bottle | Peppermint liquid; contains fish and soy; shake and refrigerate after opening. Confirm the delivered panel, since the DHA amount differs between current sources. | No human trial of this complete formula was located. Ingredient mechanisms and DHA trials do not establish a cognitive outcome for the product. |
Using the supplying-partner panel, the adult direction provides 2,300 mg DHA, 692 mg EPA, 300 mg phosphatidylserine, 1,040 mg phosphatidylcholine, 320 mg tocotrienols and 1,000 IU vitamin D3 each day. The current manufacturer DHA figure would instead total 2,400 mg daily. Check the delivered bottle before calculating intake or overlap with anything else you take.
MetaPure sits in our Daily Foundation collection and is covered in the Daily Foundation Guide. Omega Brain Plus sits in our Focus and Cognition collection; the Focus and Cognition Guide walks through its complete label and the limits of the DHA evidence.
The bottom line on dosing
Start with the supplement facts panel: EPA and DHA per serving, servings per day, and the rest of the formula. The research does not hand you a universal dose. Cognition trials have not shown a reliable outcome even when the DHA measurably reaches the brain, and the cardiovascular benefit is real but specific to high-risk patients and paired with an atrial-fibrillation signal.
So the useful question is which amount fits your situation, and whether a fish oil fits it at all. For someone raising a low intake, a moderate labelled amount taken with food is a reasonable start. For anyone managing cardiovascular risk or considering high doses, that is a conversation with a clinician, ideally with an Omega-3 Index reading in hand.
MetaPure is an EPA-dominant concentrated liquid on a once-daily 4.2 mL label. Omega Brain Plus is a DHA-dominant multicomponent liquid on a twice-daily label. Match the facts to your reason for taking one, and keep any clinical result attached to the exact intervention that produced it.
References
1 Serhan CN, Dalli J, Colas RA, et al. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochimica et Biophysica Acta. 2015;1851(4):397-413. DOI: 10.1016/j.bbalip.2014.08.006. PMID: 25139562.
2 Shahinfar H, Yazdian Z, Asgari Avini N, et al. A systematic review and dose response meta analysis of omega 3 supplementation on cognitive function. Scientific Reports. 2025;15:30610. DOI: 10.1038/s41598-025-16129-8. PMCID: PMC12368174.
3 Yassine HN, Ghasem Pour S, Juarez M, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2026;129:106316. DOI: 10.1016/j.ebiom.2026.106316. PMID: 42315445.
4 Mattumpuram J, Maniya MT, Noman A, et al. Effect of omega-3 fatty acids on cardiovascular disease risk: a systematic review and meta-analysis with meta-regression. Clinical and Translational Discovery. 2025;5:e70094. DOI: 10.1002/ctd2.70094.
5 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792. PMID: 30415628.
6 Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280. DOI: 10.1001/jama.2020.22258. PMCID: PMC7667577.
7 Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine. 2004;39(1):212-220. DOI: 10.1016/j.ypmed.2004.02.030. PMID: 15208005.
8 Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochemical and Biophysical Research Communications. 1988;152(1):328-335. PMID: 3358766.
9 Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochemical and Biophysical Research Communications. 1988;156(2):960-963. DOI: 10.1016/S0006-291X(88)80937-980937-9).
This article describes findings from published research for general educational purposes. It is not medical advice, and nothing here is intended to diagnose, treat, cure, or prevent any disease. If you take prescription medication or have a health condition, consult a qualified healthcare professional before adding a supplement.